Cannabics Pharmaceuticals Inc. (CNBX)
Market Cap | 100,616 |
Revenue (ttm) | n/a |
Net Income (ttm) | -4.57M |
Shares Out | 1.25M |
EPS (ttm) | -0.03 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 351,667 |
Open | 0.0752 |
Previous Close | 0.0826 |
Day's Range | 0.0750 - 0.0850 |
52-Week Range | 0.0750 - 25.3750 |
Beta | 1.57 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About CNBX
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and ... [Read more...]
News

CNBX Pharmaceuticals Granted Patent in Hong Kong
TEL AVIV, Israel and BETHESDA, Md. , May 5, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, today announce...

Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals
TEL AVIV, Israel and BETHESDA, Md. , March 28, 2022 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announ...

CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials
TEL AVIV, Israel and BETHESDA, Md., Nov. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago
TEL AVIV, Israel and BETHESDA, Md., Oct. 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors
TEL AVIV, Israel and BETHESDA, Md., Oct. 25, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX
TEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

CNBX Director, Dr. Inbar Maymon-Pomeranchik, to Participate at MJBizCon in Las Vegas
TEL AVIV, Israel and BETHESDA, Md., Oct. 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer
Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent applications ...

Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

Cannabics Announces New Corporate Logo, New Website and New Company Presentation
TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pio...

Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit...
TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announce...

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Heal...
TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
TEL AVIV, Israel and BETHESDA, Md., Sept. 13, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pio...

Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors
TEL AVIV, Israel and BETHESDA, Md., Aug. 23, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors
TEL AVIV, Israel and BETHESDA, Maryland, Aug. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, annou...

Cannabics Pharmaceuticals Appoints a Second Independent Board Member
TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, anno...

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
TEL AVIV, Israel and BETHESDA, Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice
TEL AVIV, Israel and BETHESDA, Md., June 28, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released ...

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Heal...
TEL AVIV, Israel and BETHESDA, Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, anno...

Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program
TEL AVIV, Israel and BETHESDA, Md., June 3, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery...
TEL AVIV, Israel and BETHESDA, Md., May 25, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations
TEL AVIV, Israel and BETHESDA, Md., May 11, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced ...

Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)
TEL AVIV, Israel and BETHESDA, Md., May 6, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Appr...
TEL AVIV, Israel and BETHESDA, Maryland, April 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, ann...